CS, Kim YS. In vivo activity of epoxide hydrolase according to sequence variation affects the progression of human IgA nephropathy.
IGA NEPHROPATHY (IGAN) IS the most common glomerulonephritis worldwide and is an important cause of end-stage renal disease (ESRD) (6) . The factors responsible for the susceptibility and progression of IgAN have not been fully elucidated, but systemic hypertension and the degree of daily proteinuria at the time of diagnosis have been shown to be associated with disease outcome (5, 26) . Genetic influences on disease susceptibility and its modification have recently been widely investigated, and the role of genetic polymorphisms in candidate genes potentially involved in the development and modification of disease has recently become an intensely studied field (1) .
Arachidonic acid is metabolized to epoxyeicosatrienoic acids (EETs) in endothelial cells by various cytochrome P-450s (33) . EETs possess potent vasodilatory (4, 8) , anti-inflammatory (21) , and fibrinolytic effects (10) and are considered to be the leading candidates for endothelium-derived hyperpolarizing factor, which mediates the relaxation of vascular smooth muscle cells (4, 8) . The soluble epoxide hydrolase (EPHX2) catalyzes the degradation of EETs to their corresponding diols and thus plays a central role in the regulation of EET levels (7) . Renal EETs are involved in renal blood flow regulation and long-term arterial blood pressure control; hence renal and cardiovascular diseases are associated with decreased renal and vascular levels of EETs (11) . We recently demonstrated a genetic effect of EPHX2 on renal allograft survival (18) .
In this study, we examined the effect of genetic variations and in vivo activity of EPHX2 on the progression of IgAN in a Korean patient cohort.
MATERIALS AND METHODS

Study population.
A total of 401 patients who gave written, informed consent were recruited from 1,318 consecutive Korean patients diagnosed with primary IgAN at Seoul National University Hospital between 1983 and 2008. The research protocol used for this study was approved by the Internal Review Board of Seoul National University Hospital (H-0704-027-205). All clinical investigations were conducted according to the principles expressed in the Declaration of Helsinki. Medical record reviews of patients were conducted using an electronic medical records system. Information on clinical parameters that could have influenced the development of chronic kidney disease was collected at the time of kidney biopsy, i.e., age, gender, blood pressure, histories of hypertension and diabetes mellitus, serum creatinine, and amount of daily proteinuria. Serum creatinine was measured with an assay based on the Jaffe' method. Estimated glomerular filtration rate (eGFR) was calculated using an abbreviated MDRD formula [186 ϫ (serum creatinine mg/dl) Ϫ1.154 ϫ (age) Ϫ0.203 ϫ (0.742 if woman)]. Hypertension was defined as a systolic blood pressure Ͼ140 mmHg or diastolic pressure Ͼ90 mmHg, or current use of antihypertensive medication. Diabetes mellitus was diagnosed if patients had a random blood glucose concentration Ն200 mg/dl, fasting plasma glucose was Ն126 mg/dl on at least two separate measurements, or if patients used antidiabetic medication. The primary outcome measure was the progression to ESRD requiring renal replacement therapy during the follow-up period. Renal replacement therapy data were obtained from the Korean ESRD registry, i.e., the Insan Memorial Dialysis Registry of the Korean Society of Nephrology (KSN) (13) . The registry contains the data for patients entering into renal replacement therapy, dialysis, or transplantation in Korea through an online registry program on the KSN website (http://www.ksn.or.kr). Information on patients who died before developing ESRD was regarded as censored. A total of 402 ethnically matched, healthy, normotensive subjects with no evidence of renal disease, who took an annual health examination at Seoul National University Hospital, were recruited as a control cohort.
Determination of genetic polymorphisms. Genomic DNA was isolated from peripheral blood mononuclear cells using a Wizard Genomic DNA Purification Kit (Promega, Madison, WI) according to the manufacturer's instructions. Three single-nucleotide polymorphisms (SNPs) spanning EPHX2 [rs41507953 (K55R), rs751141 (R287Q), and rs1042032 in the 3=-untranslated region (UTR)] were selected on the basis of their known or likely functional significance (nonsynonymous SNPs), frequency (5%), and publicly available genotype and haplotype data in the coding and noncoding regions. Genotyping was performed using the TaqMan assay (7900HT Fast real-time PCR system, Applied Biosystems, Foster City, CA). The respective forward and backward oligonucleotide primers were as follows: rs41507953, 5=-TTTCCAGAG-GACTTCTGAATGATG-3= and 5=-CATCACCACACAGAGCCCTTT-3=; rs751141, 5=-ACCGGGAGGAGCAGATGAC-3= and 5=-CATCACCA-CACAGAGCCCTTT-3=; rs1042032, 5=-ATGTAGAACGCAGCGT-GTGC-3= and 5=-ATGTGTGTAAGGCCACCTCTGTATAC-3=. Different fluorescent labels [6-carboxyfluorescein (FAM) for mutant and 6-carboxy-4,7,2=,7=-tetrachlorofluorescein (TET) for wild-type] were used to label the 5=-segments of the allelic probes. Probe sequences were as fol- . PCR products were analyzed on 2% agarose gels. Genotypes were confirmed by repeated PCR and DNA sequencing of 10% of the study population samples using an ABI Prism BigDye Terminator Kit (Applied Biosystems).
Histopathological evaluation of kidney lesions. Biopsy tissues were examined by light-, electron-, and immunofluorescence microscopy. For immunofluorescence analysis, fresh renal tissue was frozen in ornithine-carbamoyltransferase embedding compound and stained with fluorescein isothiocyanate-conjugated antisera. IgAN diagnosis was based on the presence of mesangial IgA deposition as the predominant or codominant immunoglobulin in immunofluorescence microscopy, and on the lack of clinical or laboratory evidence of systemic lupus erythematosus, Henoch-Schönlein purpura, or liver cirrhosis. All kidney histopathology specimens were evaluated by a renal pathologist in a blind fashion for the genotypes and graded in accordance with Lee's modified glomerular grading system as follows (17) : grade I, normal or focal mesangial cell proliferation; grade II, diffuse mesangial cell proliferation, or Ͻ25% of glomeruli with crescent (CR)/segmental sclerosis (SS)/global sclerosis (GS); grade III, 25-49% of glomeruli with CR/SS/GS; grade IV, 50 -75% of glomeruli with CR/SS/GS; and grade V, Ͼ75% of glomeruli with CR/SS/GS. The number of focally or completely sclerosed or crescentic glomeruli was scored as a percentage of the total number of glomeruli seen in each biopsy. Mesangial proliferation, tubulointerstitial fibrosis, and arteriolar fibrointimal thickening were graded semiquantitatively on a scale of 1-4.
Quantification of epoxyoctadecenoic acid and dihydroxyoctadecenoic acid. Plasma was obtained from 50 IgAN patients at kidney biopsy and 50 healthy, normotensive participants, selected on the basis of their rs751141 genotype [IgAN: GG (n ϭ 25), AG (n ϭ 23), AA (n ϭ 2); healthy control GG (n ϭ 25), AG (n ϭ 23), AA (n ϭ 2)]. Epoxyoctadecenoic acid (EpOME) and dihydroxyoctadecenoic acid (DiHOME) concentrations were quantified using a validated HPLC/ mass spectrometry/mass spectrometry (HPLC/MS/MS) method, as previously described (20) . A 400-l plasma sample was spiked with 50 l of internal standard [200 ng/ml of (Ϯ)12,13-DiHOME d4], and . E and F: rs1042032 polymorphism (AϾG). G: haplotype AG which is tagged by 2 variant alleles [rs751141 (A) and rs1042032 (G)].
2 ml of diethyl ether was added to each sample for liquid-liquid extraction. After vortexing for 10 min, the sample was frozen at Ϫ70°C for 30 min. The organic layer was transferred to a polypropylene conical tube and evaporated under nitrogen for 1 h. It was then reconstituted in 100 l of 1:1:1 (vol/vol/vol) acetonitrile:methanol:
water. An 80-l aliquot was transferred to an injection vial. 9,10-EpOME, 12,13-EpOME, 9,10-DiHOME, and 12,13-DiHOME were quantified by HPLC/MS/MS. The separation was performed on a Phenomenex Kinetex C18 column (50 ϫ 2.10 mm, 2.6 m, Phenomenex) set at 20°C using an Agilent 1100 series HPLC system (Agilent Technologies, Waldbronn, Germany). The mobile phase was 50:50 (vol/vol) 10 mM ammonium acetate:acetonitrile containing 0.1% formic acid at a flow rate of 0.4 ml/min. Ten microliters of the samples kept at 10°C on the autosampler were injected onto the column. Detection was achieved using an API-4000 QTRAP (Applied Biosystems) employing electrospray ionization in the negative ion mode, along with multiple reaction monitoring. Quantitation was performed by mass transition of 295.1 ¡ 171.1 (m/z) for 9,10-EpOME, 295.1 ¡ 195.0 (m/z) for 12,13-EpOME, 313.1 ¡ 201.3 (m/z) for 9.10-DiHOME, and 313.1 ¡ 183.2 (m/z) for 12,13-DiHOME. The setting parameters were as follows: curtain gas (CUR) ϭ 20 psi, collision gas (CAD) ϭ high, ion spray voltage (IS) ϭ 4,500 V, temperature heater gas (TEM) ϭ 550°C, declustering potential (DP) ϭ 90 V, and collision energy (CE) ϭ 22 V. Eleven working standards were used at concentrations of 500, 250, 150, 100, 50, 25, 10, 5, 1, 0.5, and 0.1 ng/ml.
Real-time quantitative RT-PCR. Human kidney biopsies were obtained from 50 patients with IgAN. Tissue stored in RNase inhibitor (RNAlater, Ambion, Austin, TX) was manually microdissected into glomeruli and tubulointerstitial fragments under a stereomicroscope, using two dissection needle holders. Silica gel-based RNA was isolated using an RNeasy-Mini kit (Qiagen, Hilden, Germany) from tubulointerstitial fragments, and 1 g of RNA was reverse transcribed using oligo-d(T) primers and AMV-RT polymerase (Promega) (27) . Real-time RT-PCR was performed using Assay-on-Demand Taqman probes and primers for EPHX2 and GAPDH (Applied Biosystems) with an ABI PRISM 7500 Sequence Detection System. All PCR reactions were performed in duplicate. The results were normalized with respect to GAPDH expression.
Statistical analysis. Genotype frequencies were estimated by gene counting. Allele frequencies were deduced from the genotype distribution. The observed allele frequencies did not differ significantly from the allele frequencies predicted by the Hardy-Weinberg equilibrium. Pairwise linkage disequilibrium statistics were calculated, and haplotypes were reconstructed separately. Haplotypes and their frequencies were estimated using the phase reconstruction method (PHASE 2.1), which assigned the most probable haplotype pair to each individual. The distributions of the SNP genotypes and allele frequencies between IgAN patients and controls were analyzed using 2 tests. Continuous and categorical data were compared between the whole group of IgAN patients in our center and the patients included in this study using an independent t-test and the 2 test. Baseline clinical characteristics among the different genotypes were compared using a Cochran-Armitage test and Jonckheere test. We used SAS PROC CORR with the Kendall option because the P value for the Kendall statistic is equivalent to the two-tailed P value for the Jonckheere statistic. Renal survival rates were calculated using the Kaplan-Meier method, and comparisons between groups were performed using the log-rank test. The Cox proportional hazard regression model was used to calculate unadjusted and adjusted hazard ratios (HRs) and 95% confidence intervals (CIs) for multivariate analysis. All stastistical analyses were performed using SAS software. P values Ͻ0.05 were considered significant.
RESULTS
Baseline characteristics and genetic variations.
The baseline characteristics of patients in this study were not significantly different from the whole IgAN cohort except for gender ( Table 1 ). The median observational period was 6.2 yr, and the number of patients who developed ESRD was 99. No variant rs41507953 (K55R) allele polymorphisms were detected in the study population. The frequencies of the GG, GA, and AA rs751141 genotypes were 55.1, 39.2, and 5.7% and the frequencies of the AA, AG, and GG rs1042032 genotypes were 34.9, 49.4, and 15.7%, respectively, in IgAN patients. Minor allele frequencies of rs751141 and rs1042032 were 0.253 and 0.402, respectively. There were no significant differences in allele frequencies between the IgAN and normal control (Supplementary Table S1 ; all supplementary material for this article is available online at the journal web site). Comparison of baseline characteristics according to the respective polymorphisms revealed that systolic blood pressure and initial eGFR differed significantly among rs751141 genotypes (Table 1) ; patients homozygous for the GG allele had higher systolic blood pressure and poorer renal function than other groups.
Genetic variations and IgAN progression. Survival analysis using the Kaplan-Meier method revealed that heterozygous GA and homozygous AA patients, i.e., those carrying the rs751141 polymorphism variant allele, showed better survival rates than wild-type homozygotes (GG) in the log-rank test (Fig. 1, A and B, P ϭ 0.003, Ͻ0.001, respectively). However, there was no significant association between the rs1042032 EPHX2 gene polymorphism and IgAN progression (Fig. 1, E and F) .
Univariate and multivariate Cox regression analyses were performed after adjustment for several factors. Unadjusted Cox regression analysis revealed that individuals with the rs751141 GG genotype had an increased HR for kidney failure (GG vs. GAϩAA genotype, HR 2.10, 95% CI 1.35-3.25, P ϭ 0.001). This association was significant after adjustment for several risk factors (model 4, HR 1.83, 95% CI 1.13-2.96, P ϭ 0.014) ( Table 2 ). However, the association was not significant after adjustment for initial eGFR (model 5, HR 1.21, 95% CI 0.73-2.01, P ϭ 0.453). Because interaction between initial eGFR and rs751141 genotypes was significant, we divided the patients into two groups (eGFR Ͻ60 and Ն60 ml·min Ϫ1 ·1.73 m Ϫ2 ) according to initial eGFR and performed subgroup analyses. There were no significant differences in baseline characteristics among the genotypes in either subgroup, according to the respective polymorphisms (Supplement Table S2 ). The rs751141 genotype had no effect on renal survival in the Fig. 1C) . However, the rs751141 GG genotype was a significant risk factor for ESRD in subjects with baseline eGFR Ն60 ml·min Ϫ1 ·1.73 m Ϫ2 (n ϭ 257, 85.2 Ϯ 21.4 ml·min Ϫ1 ·1.73 m Ϫ2 ), even after adjustment for age, sex, hypertension, diabetes, initial proteinuria, and initial eGFR (HR 2.45, 95% CI 1.14 -5.24, P ϭ 0.021) (Fig. 1D, Table 3 ).
rs751141 genetic variations and renal pathology of IgAN. We examined 364 IgAN pathological findings according to the rs751141 polymorphisms (GG, n ϭ 198; GA, n ϭ 147; AAϭ19). Mesangial expansion, tubulointerstitial damage, and glomerular damage grades were similar among the groups (Table 4) . Vascular fibrointimal thickening, however, was significantly more severe in the GG group than in other groups (Table 4 and Fig. 2A , P Ͻ 0.01).
rs751141 biomarker analysis and real-time quantitative RT-PCR. Biomarker analysis and real-time quantitative RTPCRs were performed as in vivo studies to investigate the functional relationship between EPHX2 sequence variation and IgAN progression.
IgAN patients (n ϭ 25) with one (GA) or two (AA) copies of the variant rs751141 allele demonstrated significantly higher plasma 9,10-and 12,13-EpOME-to-DiHOME ratios, compared with wild-type (GG) individuals (n ϭ 25) (9,10-EpOME/ DiHOME GG: 0.96 Ϯ 0.10 vs. GGϩAA: 1.52 Ϯ 0.18, P ϭ 0.027; 12,13-EpOME/DiHOME GG: 1.15 Ϯ 0.09 GGϩAA: 1.68 Ϯ 0.18, P ϭ 0.020), apparently indicative of lower EPHX2 activity in vivo (Fig. 2B) . The pattern in the normal controls was similar that of IgAN patients, but it was not statistically significant.
The gene expression level of EPHX2 in microdissected human renal tubular segments [GG (n ϭ 25), AG (n ϭ 23), AA (n ϭ 2)] was not significant between wild-type (GG) individuals and GAϩGG patients (P ϭ 0.306, Fig. 2C) .
Haplotype association analysis. We investigated the existence of a combined effect of SNPs in the EPHX2 gene on the progression of IgAN. Haplotype reconstruction, including rs751141 and rs1042032 polymorphisms, identified three common haplotypes for 99.9% of all chromosomes (Table 4) . Pairwise linkage disequilibrium measurement between the rs751141 polymorphism and the rs1042032 polymorphism in the EPHX2 gene gave values of D= ϭ 0.99 and ␥ 2 ϭ 0.49. Haplotype AG with both minor alleles (frequency, 24.3%) was associated with a significantly lower risk of IgAN progression. The Kaplan-Meier method showed that patients with at least one copy of haplotype AG showed good renal survival compared with patients without this haplotype (P Ͻ 0.001, log-rank test) (Fig. 1G) . Unadjusted Cox regression analysis revealed that individuals carrying at least one copy of haplotype AG had a 0.45-fold decreased HR for IgAN progression (95% CI 0.29 -0.71, P Ͻ 0.001). This association was significant after adjustment for several risk factors, including age, gender, hypertension, and initial proteinuria (Ͼ1 g/day, model 4, HR ϭ 0.52, 95% CI 0.32-0.84, P ϭ 0.008) ( Table 5) .
DISCUSSION
In the present study, we analyzed three polymorphisms of the EPHX2 gene known to be associated with enzyme activity, and which might therefore modify the natural disease course of IgAN. None of the polymorphism frequencies differed significantly between IgAN patients and normal controls. However, patients with the variant rs751141 allele polymorphism had a better prognosis of IgAN than those with the wild-type allele via modulating the in vivo enzyme activity, which is independent of gene expression. These results thus identified a significant association between genetic variation in EPHX2 and the risk of IgAN progression.
IgAN is the most common primary glomerulonephritis and one of the leading causes of ESRD, especially in eastern Asia (28) . However, its etiology and pathogenesis remain unclear. Among the known risk factors for poor renal outcome (5, 26) , some genetic polymorphisms may also be associated with IgAN progression (2, 12, 14, 19, 30) . However, despite inten- sive efforts to elucidate the genetic background of IgAN, the genetic factors associated with the pathogenesis of this disease are still not well understood.
EETs have potent vasodilatory effects and are considered likely to represent one of the endothelium-derived hyperpolarizing factors (4) and also have anti-inflammatory effects (21) . They prevent endothelial dysfunction via these vasodilatory and anti-inflammatory effects, and renal and cardiovascular diseases are considered to be associated with decreased levels of kidney and vascular EETs (11). In vitro studies have shown that rs41507953 and rs751141 polymorphisms modify the activity of EPHX2, which inactivates EETs through hydrolysis. The rs41507953 polymorphism increases the activity of EPHX2. One recent study found that the variant rs41507953 allele polymorphism was associated with a significantly higher risk of developing coronary heart disease in Caucasians and also proposed an in vivo effect of the rs41507953 polymorphism (29) . However, no variant rs41507953 allele polymorphism was identified in the current study population. There have been no reports of rs41507953 polymorphism in the Asian population to date, and only two nonsynonymous polymorphisms [rs751141 (R287Q) and rs4149251 (S407I)] of the EPHX2 gene have been identified (23, 31) . This suggests that the rs41507953 polymorphism may be absent from the Asian population. The minor allele frequencies of the rs751141 and rs1042032 polymorphisms in the Japanese population are 19.5 and 45.1%, respectively (31) . These results are in agreement with the present study. The rs751141 polymorphism has been shown to decrease the activity of EPHX2 in vitro (22, 24, 29) . The variant rs751141 allele polymorphism is therefore considered to be a good prognostic factor in cardiovascular and kidney disease. In the current study, patients with the variant rs751141 allele polymorphism had a significantly higher renal survival rate than those patients with the wild-type genotype. Moreover, this association between disease progression and genotype was found to be independent of age, gender, hypertension, and daily proteinuria. This result is in agreement with the outcome of previous studies (3, 9, 16) . The rs1042032 polymorphism, however, was not independently associated with IgAN progression.
Baseline systolic blood pressure and initial eGFR differed significantly according to the respective rs751141 polymorphisms. It may raise the issue of selection bias. However, there were no significant differences in characteristics between the present study population and all IgAN patients in our institute for the same duration; therefore, the patients could be the representatives of the whole cohort. Furthermore, subgroup analysis found no differences among the groups, and the association between rs751141 polymorphism and IgAN progression remained statistically significant in the subgroup with good renal function, even after adjustment for several risk factors including initial eGFR. In addition, histological analysis of renal biopsy specimens showed differences in vascular damage according to the presence of rs751141 polymorphisms. This result is consistent with the results of earlier studies indicating that the soluble epoxide was preferentially expressed in the human renal vasculature, and supporting an essential role for this enzyme in renal hemodynamic regulation (32) . We observed lower apparent in vivo EPHX2 activity in IgAN patients carrying at least one rs751141 variant allele, as measured by EpOME/DiHOME ratios (15, 20) . We suggest that the rs751141 variant allele decreases EPHX2 activity in IgAN patients and affects intrarenal blood pressure, delaying the deterioration of renal function. Although the EPHX2 activity pattern in the normotensive participants was similar with that of IgAN patients, it was not statistically significant. The rs751141 variant allele per se seems to decrease in vivo activity, and pathological condition such as IgAN might further reduce the activity. That mRNA expression was not different between wild-type (GG) individuals and GAϩGG patients is postulated as the R287Q variant affects enzyme activity and not transcription. However, there are some controversies suggesting that carriers of the rs751141 variant allele are at increased risk of developing cardiovascular disease (9, 25) and insulin resistance in Japanese type 2 diabetic patients (25) . Therefore, a validation study will be necessary.
In this study, haplotypes tagged by both variant alleles had better renal survival rates than others, after adjustment for age, gender, hypertension, and daily proteinuria. The predictive power of haplotype analysis for kidney survival was stronger than that of single polymorphism-based analysis. This finding could support the fact that haplotypes, rather than individual variants, define the functional units of genes.
In conclusion, the genetic variation of rs751141 was associated with IgAN progression, and the regulation of EPHX2 activity could provide a potential therapeutic target in patients with chronic glomerulonephritis. 
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